Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

A phase II non-randomized single arm trial of oral panobinostat (LBH589) was conducted in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS). The objective of this study was to determine the clinical efficacy, safety, and tolerability of panobinostat in this patient population....

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Dimicoli, Sophie, Jabbour, Elias, Borthakur, Gautam, Kadia, Tapan, Estrov, Zeev, Yang, Hui, Kelly, Mary, Pierce, Sherry, Kantarjian, Hagop, Garcia-Manero, Guillermo
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4085038/
https://ncbi.nlm.nih.gov/pubmed/22072492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.22198
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires